Is BPC-157 legal in Japan? Approval, personal import and anti-doping rules in 2026
Short answer: BPC-157 is not an approved medicine in Japan, so it cannot lawfully be sold or advertised there as one, and importing it for your own use is limited by MHLW's personal-import rules. It does not appear in PMDA's package-insert database for prescription drugs marketed in Japan, and Japan's Pharmaceutical and Medical Devices Act (the PMD Act, 薬機法) requires approval for each product before a medicine is marketed. Personal imports above set quantities need an import confirmation certificate (輸入確認証), which replaced Yakkan Shoumei (薬監証明) on 1 September 2020. For tested athletes it is banned at all times: the WADA 2026 Prohibited List names it in class S0. This page gives each rule with its official source and says what PeptideGuide could not confirm.
Approval: Article 14(1) of the PMD Act requires anyone who manufactures and markets a medicine in Japan to obtain the Minister of Health, Labour and Welfare's approval for each product (PMD Act on e-Gov). BPC-157 does not appear in PMDA's package-insert database for prescription drugs marketed in Japan: PeptideGuide searched it on 7 October 2026 under BPC-157, BPC157, Body Protection Compound and Japanese name variants and found no entry. WADA reaches the same point from another direction. Its class S0 covers substances "with no current approval by any governmental regulatory health authority for human therapeutic use", and the 2026 Prohibited List names BPC-157 in that class.
Is it a "medicine" under the Act? Article 2(1) defines a medicine by its intended purpose: a product meant to diagnose, treat or prevent disease in people or animals, or to affect the structure or function of the body. Where BPC-157 is sold with a "research use only" label, PeptideGuide found no Japanese government statement on how that label affects the Article 2 test, so this page does not claim the label takes a product outside the Act.
Selling and advertising: selling medicines as a business requires a pharmacy or sales licence (Article 24(1)). A medicine marketed without the Article 14 approval may not be sold, supplied, or stored or displayed for sale (Article 55(2)), and no one may advertise the name, effects or performance of a medicine that has not been approved (Article 68). Breaching Article 14(1), 24(1) or 55(2), or importing a medicine without a confirmation that Article 56-2(1) requires, is punishable by up to three years' imprisonment, a fine of up to ¥3 million, or both (Article 84).
Personal import: an individual may import medicines for their own use within set quantities after a customs check. The limits are one month's supply at the labelled dosage for prescription drugs and poisonous or powerful drugs, 24 standard-size units per item for external-use products, and two months' supply for other medicines (MHLW personal-import page; Japan Customs). Above those quantities, the importer must first obtain an import confirmation certificate (輸入確認証) from a Regional Bureau of Health and Welfare and show it to customs. MHLW's English page for travellers lists "Injectable drug and Syringe for the drug" at up to one month's supply, with a note limiting that row to pre-filled syringes or self-injection kits (MHLW, English). None of these pages says which category applies to a research-labelled BPC-157 vial.
Products that need a prescription in any quantity: MHLW keeps a list of medicines that individuals may not import in any quantity unless a doctor's prescription can be confirmed, because self-use could cause serious harm. BPC-157 does not appear in the February 2025 edition of that list (MHLW, PDF).
Yakkan Shoumei is gone: MHLW states that items previously imported with Yakkan Shoumei (薬監証明) have needed an import confirmation certificate instead since 1 September 2020, and applications can be filed through an online system that started on 1 February 2023. Under MHLW's import-confirmation guideline (revised 30 June 2025), a personal-use application above the limits is filed with a product description, a copy of a doctor's prescription or instructions, the invoice and the air waybill. The listed documents do not include proof that the product is approved in another country. Japan Customs describes the certificate as confirmation that the import is not for sale.
No sharing: imported medicines are for the importer alone. MHLW does not allow selling or giving them to anyone else, or importing other people's portions together, and its guideline adds that handing them to another person for that person's use is not allowed even free of charge.
Research labs: under the same guideline, importing unapproved medicines for testing and research (quality, pharmacology or formulation tests) also needs import confirmation, filed with a research plan (試験研究計画書). Clinical trials are a separate route: anyone requesting or conducting a clinical trial (治験) must notify the Minister of the trial plan in advance under Article 80-2(2) of the PMD Act.
Designated substances: BPC-157 does not appear on Japan's list of designated substances (指定薬物), which covers substances likely to act on the central nervous system, in the edition with designations up to 18 August 2026 (MHLW). PeptideGuide did not check Japan's narcotics and psychotropics schedules.
Warnings: PeptideGuide found no Japanese government warning that names BPC-157. The information site MHLW runs through its personal-import project, Ayashii Yakubutsu Renraku Net, republished a Health Canada notice listed under 24 December 2025 about unapproved health products seized at Rize Fitness, and "PHX Labs BPC-157" is one of the products named. That is a Canadian finding reprinted in Japan, not a Japanese ruling.
Athletes: the WADA 2026 Prohibited List names BPC-157 in class S0 (non-approved substances), which is prohibited at all times, in and out of competition. JADA publishes the list in Japanese and English and states that the 2026 list applies until 31 December 2026 (JADA). Wider context is in JADA and WADA peptide bans for Japanese athletes.
What this page does not establish: whether customs or a Regional Bureau would treat a research-labelled BPC-157 vial as a prescription drug, an injectable or another medicine for the quantity limits; how often such parcels are stopped; and how penalties are applied to individual buyers. PeptideGuide found no official source for these points. Framework background is in the PMD Act and research peptides and what replaced Yakkan Shoumei.
Is BPC-157 legal in Japan?
It is not an approved medicine in Japan, so selling or advertising it as one breaks the PMD Act. It is not on the designated-substances list, and individuals may import medicines for their own use within MHLW limits, with an import confirmation certificate needed above them (MHLW). No official source says which limit applies to a research-labelled vial. For tested athletes it is prohibited at all times under WADA class S0.
Is BPC-157 an approved drug in Japan?
No approval was found. BPC-157 does not appear in PMDA's package-insert database for prescription drugs marketed in Japan (searched 7 October 2026). WADA's 2026 list places it in class S0, which covers substances with no current approval by any government health authority for human therapeutic use.
Can I import BPC-157 into Japan for personal use?
MHLW lets individuals import medicines for their own use after a customs check, within limits: one month's supply for prescription drugs, two months' for most other medicines, and one month's supply of injectables in pre-filled syringes or self-injection kits. Above the limits you need an import confirmation certificate from a Regional Bureau of Health and Welfare, filed with a copy of a doctor's prescription or instructions (MHLW guideline). PeptideGuide found no official page that says which limit applies to research-labelled BPC-157.
What replaced Yakkan Shoumei?
The import confirmation certificate (輸入確認証, Yunyu Kakunin-sho). MHLW states that from 1 September 2020 it is obtained in place of Yakkan Shoumei (薬監証明), and applications can be filed through an online system that started on 1 February 2023. The full explainer is at what replaced Yakkan Shoumei.
Can I share or resell BPC-157 I imported?
No. MHLW says personally imported medicines may not be sold or given to anyone else, and its import-confirmation guideline adds that this applies even free of charge. Importing other people's portions together is not allowed either.
Can a Japanese laboratory import BPC-157 for research?
Importing unapproved medicines for quality, pharmacology or formulation testing needs import confirmation with a research plan (試験研究計画書) under MHLW's guideline. Clinical trials (治験) need a trial-plan notification to the Minister in advance under PMD Act Article 80-2(2).
Is BPC-157 banned for athletes in Japan?
Yes. The WADA 2026 Prohibited List names BPC-157 in class S0, which is prohibited at all times, and JADA applies the 2026 list in Japan until 31 December 2026 (JADA).
What are the penalties under the PMD Act?
Marketing a medicine without approval, selling medicines without a licence, or selling unapproved medicines (breaches of Articles 14(1), 24(1) and 55(2)) is punishable by up to three years' imprisonment, a fine of up to ¥3 million, or both under Article 84 (e-Gov). Importing a medicine without a confirmation that Article 56-2(1) requires carries the same maximum. PeptideGuide found no official source on how these penalties are applied to individual buyers.
More from this region.
Other articles covering this region's vendors, regulatory framework, and research peptides.